Partnering is an integral part of our strategy at Vernalis. We actively in-license and out-license programmes as well as enter into research and development collaborations.  We seek to in-license late-stage, low risk assets that will complement our cough cold commercial strategy in the US, illustrated by our acquisition of the US rights to Moxatag®.


  • In-licensing opportunities sought to complement our US commercial strategy
  • Promising candidates ready for out-licensing now
  • Research partnerships


Established track-record with a number of large pharmaceutical companies

Partners include Genentech, Lundbeck, Novartis, Servier, Tris and others

Why partner with Vernalis?

We have a number of promising partnership opportunities

Sharing the risks and rewards of late stage development with suitably qualified partners

Out-licensing opportunities

Vernalis actively seeks late-stage, low risk assets

Suitable assets would complement our cough cold strategy in the US

In-licensing opportunities

Luminespib (AUY922) is an Hsp90 inhibitor that has been studied in a large number of phase I/II data and is indicated for the treatment of a broad range of cancers.

Read more about Luminespib (AUY922)

A selective FAAH (fatty acid amide hydrolase) inhibitor

V158866 is our lead molecule with potential application in pain and neurology indications.  This programme is currently on hold.

Read more about V158866

A selective Chk1 (checkpoint 1) inhibitor

V158411, is the lead molecule potentially indicated for treatment of a broad range of cancers 

Read more about V158411

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and or FDA at 1-800-FDA-1088 or